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Background: Traditional cardiovascular risk factors, such as hypertension and dyslipidemia, predispose individuals to cardiovascular disease, particularly patients with diabetes. We investigated the predictive value of baseline systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) on the risk of vascular outcomes in a large population of patients at high risk of future cardiovascular events.
Methods: Data were pooled from the TNT (Treating to New Targets), IDEAL (Incremental Decrease in End-Points Through Aggressive Lipid Lowering), and CARDS (Collaborative Atorvastatin Diabetes Study) trials and included a total of 21,727 patients (TNT: 10,001; CARDS: 2838; IDEAL: 8888). The effect of baseline SBP and LDL-C on cardiovascular events, coronary events, and stroke was evaluated using a multivariate Cox proportional-hazards model.
Results: Overall, risk of cardiovascular events was significantly higher for patients with higher baseline SBP or LDL-C. Higher baseline SBP was significantly predictive of stroke but not coronary events. Conversely, higher baseline LDL-C was significantly predictive of coronary events but not stroke. Results from the subgroup with diabetes (5408 patients; TNT: 1501; CARDS: 2838; IDEAL: 1069) were broadly consistent with those of the total cohort: baseline SBP and LDL-C were significantly predictive of cardiovascular events overall, with the association to LDL-C predominantly related to an effect on coronary events. However, baseline SBP was not predictive of either coronary or stroke events in the pooled diabetic population.
Conclusions: In this cohort of high-risk patients, baseline SBP and LDL-C were significantly predictive of cardiovascular outcomes, but this effect may differ between the cerebrovascular and coronary systems.






Observational studies have linked blood pressure (BP) and serum cholesterol to vascular mortality in patients with  ADDIN EN.CITE [,] and without  ADDIN EN.CITE [,] type 2 diabetes. Many large clinical trials have found that control of these risk factors corresponds to a reduction in the rates of cardiovascular outcomes  ADDIN EN.CITE [,]. Systolic BP (SBP) is a recognized risk factor for cardiovascular disease (CVD), and is strongly associated with stroke mortality []. The relationship between cholesterol and coronary heart disease (CHD) is well established  ADDIN EN.CITE [,]. However, the association between cholesterol and stroke mortality is controversial  ADDIN EN.CITE [,].
Patients with diabetes are at increased risk of cardiovascular events compared with nondiabetic patients such that those with diabetes but without prior myocardial infarction (MI) have a coronary risk similar to those without diabetes but with a history of previous MI []. Baseline SBP has been shown to be predictive of cardiovascular events within this high-risk population  ADDIN EN.CITE []. When adjusted for age and sex, low-density lipoprotein cholesterol (LDL-C) is a significant driver of CHD risk among patients with diabetes [].
In this analysis, we assessed the effect of baseline SBP and baseline LDL-C on cardiovascular events, coronary events, and stroke in patients at high risk for cardiovascular events. By pooling the populations from three large clinical trials, which provide detailed information on patients’ medical history and subsequent cardiovascular events, we were able to conduct an in-depth analysis of a large population of high-risk patients.
2. Methods
2.1. Study design, participants and outcomes 
A total of 21,727 patients (10,001 from TNT [Treating to New Targets], 2838 from CARDS [Collaborative Atorvastatin Diabetes Study], and 8888 from IDEAL [Incremental Decrease in End Points Through Aggressive Lipid Lowering]) were included in this analysis. Two pooled datasets were analyzed: one contained the entire TNT, CARDS, and IDEAL populations; the other contained the diabetic patients from TNT (n = 1501), IDEAL (n = 1069), and CARDS (n = 2838). TNT, CARDS, and IDEAL were large, prospective, parallel-group studies evaluating atorvastatin in high-risk populations and have been described in detail elsewhere  ADDIN EN.CITE []. All patients gave informed written consent, and studies were approved by local research ethics committees or institutional review boards at each participating center.
TNT (NCT00327691) was a large, double-blind, parallel-group trial with a median follow-up of 4.9 years. After an 8-week run-in period on atorvastatin 10 mg/day, patients with stable CHD and a mean serum LDL-C concentration <130 mg/dL (3.4 mmol/L) were randomized to treatment with atorvastatin 80 mg/day (n = 4995) or 10 mg/day (n = 5006). The primary endpoint was time to a major cardiovascular event (MCVE), defined as CHD death, nonfatal MI, resuscitated cardiac arrest, and fatal or nonfatal stroke []. Secondary study outcomes included major coronary events, any coronary event, cerebrovascular events, peripheral vascular disease, hospitalization with a primary diagnosis of congestive heart failure, any cardiovascular event, and all-cause mortality.
CARDS (NCT00327418) was a double-blind, placebo-controlled trial with a median follow-up of 3.9 years. Patients with type 2 diabetes and one other CHD risk factor (retinopathy, albuminuria, current smoking, or hypertension), but no history of CVD and a mean LDL-C <160 mg/dL (4.14 mmol/L) were randomized to placebo (n = 1410) or atorvastatin 10 mg/day (n = 1428). The primary endpoint was time to an MCVE, consisting of acute coronary events, coronary revascularization, or stroke [].
IDEAL (NCT00159835) was a prospective, randomized, open-label, blinded endpoint trial with a median follow-up of 4.8 years. Patients with a history of acute MI were randomized to treatment with atorvastatin 80 mg/day (n = 4439) or simvastatin 20 mg/day (n = 4449), with the option of titrating to 40 mg/day at Week 24. The primary endpoint was time to first occurrence of a major coronary event, defined as coronary death, nonfatal MI, or cardiac arrest with resuscitation  ADDIN EN.CITE []. Secondary endpoints included MCVEs, defined as major coronary events and stroke.
2.2. Statistical analyses 
SBP has been shown to be an informative single measurement in predicting cardiovascular risk  ADDIN EN.CITE [,]. The predictive effect of a 10-mmHg increase in baseline SBP and a 10-mg/dL (0.26-mmol/L) increase in baseline LDL-C on cardiovascular events, coronary events, and stroke was evaluated using multivariate Cox proportional hazards models. Baseline SBP and baseline LDL-C were included in each model as predictor variables. To enhance the predictive model, additional predictors were entered into the model using stepwise selection, with an entry criterion of p = 0.05, and the following demographics and baseline characteristics were considered: age, diastolic BP, body mass index (BMI), triglycerides (log-transformed), high-density lipoprotein cholesterol, gender, smoking history, and history of diabetes, hypertension, ischemic heart disease (IHD), or stroke or transient ischemic attack (TIA).
The analysis was performed on each study separately and on pooled data from the three studies, both for the total population and for the subset of patients with diabetes. Analyses of the pooled study data were stratified by study. The interactions between the four treatments represented in the studies and baseline SBP, and between treatment and baseline LDL-C, were assessed for the pooled analysis.
Statistical analyses were performed using SAS 9.1 or later (SAS Institute, Cary, NC, USA). Two-sided p-values < 0.05 were considered statistically significant.
3. Results
3.2. Study population
Baseline characteristics that were similar between the TNT, CARDS, and IDEAL populations included age and BMI (Table 1). All of the participants in CARDS had type 2 diabetes, compared with 15% in TNT and 12% in IDEAL. Other differences in baseline characteristics included gender, smoking status, hypertension, and history of IHD. In the total pooled population, the mean age was 61.4 years, mean SBP was 135 mmHg, and mean LDL-C was 110 mg/dL (2.8 mmol/L) at baseline; 24.9% of patients had type 2 diabetes and nearly half of the patients had hypertension (Table 1). The most frequently used concomitant medications among patients included in the pooled analysis were beta-adrenoceptor-blocking drugs (33.8%), lipid-lowering drugs (31.9%), antihypertensive drugs (excluding beta-blockers; 27.5%), vasodilators (19.3%), and anticoagulants (12.1%).
During a median follow-up of 3.9–4.9 years, a total of 4489 (20.7%) patients experienced a CHD event and 657 (3.0%) patients experienced a stroke event in the pooled population overall. The incidence of CHD events and stroke events was lower in CARDS compared with TNT and IDEAL (Table 2). In the pooled diabetic population, a total of 849 (15.7%) patients had a CHD event and 207 (3.8%) patients had a stroke event. The proportion of patients with CHD and stroke events was greater in the diabetic TNT and IDEAL populations compared with the TNT and IDEAL populations overall (Table 2).
3.3. Effect of baseline SBP in the total study populations
Each 10-mmHg increase in baseline SBP was associated with a significantly increased risk of all cardiovascular events in the TNT, CARDS, IDEAL, and total pooled populations (Fig. 1A). Increased SBP at baseline was associated with a significantly increased risk of all coronary events in the IDEAL population, but not the TNT (p = 0.6607), CARDS (p = 0.2987), or the total pooled (p = 0.1778) populations (Fig. 1B). A 10-mmHg increase in baseline SBP significantly increased the risk of stroke in the TNT and the total pooled populations, but not in the CARDS (p = 0.1502) or IDEAL (p = 0.1762) populations (Fig. 1C). There were no significant interactions between baseline SBP and the four treatment regimens for cardiovascular events, coronary events, or stroke in the pooled analysis (data not shown).
3.4. Effect of baseline LDL-C in the total study populations
Each 10-mg/dL increase in baseline LDL-C was associated with a significantly increased risk of both cardiovascular and coronary events in the TNT, CARDS, IDEAL, and total pooled populations (Fig. 2A, Fig. 2B). However, a 10-mg/dL increase in baseline LDL-C was not associated with a significant increase in the risk of stroke in the TNT (p = 0.1027), CARDS (p = 0.5835), IDEAL (p = 0.9589), or total pooled (p = 0.4004) populations (Fig. 2C). There were no significant interactions between baseline LDL-C and the four treatment regimens for cardiovascular events or stroke for the pooled analysis (data not shown); however, significant interactions were found between baseline LDL-C and the four treatments for coronary events. The hazard ratios (HRs) and 95% confidence intervals (CIs) for the interactions between baseline LDL-C and atorvastatin 80 mg, baseline LDL-C and atorvastatin 10 mg, baseline LDL-C and simvastatin 20 mg, and baseline LDL-C and placebo were 1.05 (1.04–1.07), 1.08 (1.05–1.11), 1.03 (1.01–1.05), and 1.13 (1.04–1.24), respectively.
3.5. Effect of baseline SBP in the diabetic populations
Each 10-mmHg increase in baseline SBP significantly increased the risk of cardiovascular events in the CARDS and pooled diabetic populations, but not in the diabetic TNT (p = 0.4641) or IDEAL (p = 0.2341) populations (Fig. 3A). A 10-mmHg increase in baseline SBP did not significantly increase the risk of coronary events in the diabetic TNT (p = 0.7282), CARDS (p = 0.2987), IDEAL (p = 0.2117), or pooled diabetic (p = 0.7821) populations (Fig. 3B). Similarly, a 10-mmHg increase in baseline SBP did not significantly increase the risk of stroke in the diabetic TNT (p = 0.3028), CARDS (p = 0.1502), IDEAL (p = 0.9238), or pooled diabetic (p = 0.2497) populations (Fig. 3C). No significant interactions were observed between baseline SBP and the four treatments for cardiovascular events, coronary events, or stroke for the pooled diabetic population (data not shown).
The patients with diabetes included in these trials were hypertensive (mean [SD] SBP 140.6 [17.6] mmHg vs 133.1 [18.6] mmHg for nondiabetic patients), which may have limited the spread of SBP values and thus contributed to the lack of association between incremental increase in baseline SBP and stroke risk in the diabetic populations. Therefore, a sensitivity analysis was performed forcing history of hypertension into the model to assess the relationship between hypertension and stroke risk in these patients. However, history of hypertension also was not predictive of a significant increase in stroke risk in the diabetic TNT (p = 0.0755), CARDS (p = 0.4455), IDEAL (p = 0.3179), or pooled diabetic (p = 0.1346) populations.
3.6. Effect of baseline LDL-C in the diabetic populations
Each 10-mg/dL increase in baseline LDL-C was associated with a significantly increased risk of cardiovascular events in the CARDS and pooled diabetic populations, but not in the diabetic TNT (p = 0.0923) or IDEAL (p = 0.4452) populations (Fig. 4A). Similarly, an incremental increase in baseline LDL-C significantly increased the risk of coronary events in the CARDS and pooled diabetic populations, but not in the diabetic TNT (p = 0.2767) or IDEAL (p = 0.3260) populations (Fig. 4B). Although a 10-mg/dL increase in baseline LDL-C significantly increased the risk of stroke in the diabetic TNT population, it was not associated with increased stroke risk in the CARDS (p = 0.5835), diabetic IDEAL (p = 0.3948), or pooled diabetic (p = 0.6953) populations (Fig. 4C). No significant interactions were found between baseline LDL-C and the four treatment regimens for cardiovascular events or stroke for the pooled diabetic population (data not shown); however, significant interactions were observed between baseline LDL-C and the four treatments for coronary events. The HRs (95% CIs) for the interactions between baseline LDL-C and atorvastatin 80 mg, baseline LDL-C and atorvastatin 10 mg, baseline LDL-C and simvastatin 20 mg, and baseline LDL-C and placebo were 1.00 (0.96–1.05), 1.08 (1.01–1.14), 1.03 (0.98–1.08), and 1.14 (1.04–1.24), respectively.
4. Discussion
This analysis found baseline SBP and LDL-C to be predictive of cardiovascular outcomes for high-risk patients, which included both primary and secondary prevention populations. Overall, each additional 10-mmHg increment in baseline SBP or 10-mg/dL increment in baseline LDL-C was associated with a relative increase in risk of cardiovascular events (3% for SBP; 4% for LDL-C). However, the effects of baseline SBP and LDL-C differed between coronary and cerebrovascular beds.
4.1. SBP and cardiovascular risk
Although numerous epidemiologic studies have demonstrated a continuum of cardiovascular risk across levels of SBP that is independent of age, gender, and ethnicity and is consistent within and between countries  ADDIN EN.CITE [,,], the results from clinical trials investigating the effect of BP-lowering agents to reduce cardiovascular risk have provided unequivocal evidence of the association between BP and CVD []. Moreover, intensive BP-lowering has been shown to provide an incremental benefit over less intensive regimens in reducing cardiovascular risk  ADDIN EN.CITE [].
The association between elevated BP and CVD is particularly notable for stroke risk, and the benefits of BP lowering to reduce stroke are widely known. In the Prospective Studies Collaboration meta-analysis, SBP was found to be strongly predictive of stroke mortality, with each 20-mmHg increase in SBP associated with a >2-fold increase in the risk of death from stroke []. A subsequent review and meta-analysis of major cohort studies and clinical trial data found that each 10-mmHg decrease in SBP was associated with a reduction in risk of stroke of around one-third, and this correlation was consistent across stroke subtypes for both fatal and nonfatal events in a wide range of patient populations []. An extensive meta-analysis of 147 BP-lowering trials including 464,164 patients by Law et al. also estimated a one-third decrease in the risk of stroke for each 10-mmHg reduction in SBP []. A previous subanalysis of data from the TNT study population found that hypertension was predictive of cerebrovascular events (HR 1.94; 95% CI 1.59–2.37; p < 0.0001) []. Similarly, CARDS patients with stroke had higher baseline SBP than those without stroke (HR for 10-mmHg increase: 1.17; 95% CI 1.01–1.36; p = 0.044)  ADDIN EN.CITE []. In our pooled analysis, the risk of fatal or nonfatal stroke was shown to increase by 6% with each additional 10-mmHg increment in baseline SBP. Our findings are broadly consistent with data from observational studies that have indicated that death from stroke increases progressively and linearly from SBP levels as low as 115 mmHg.
The risk of coronary events has also been shown to be related to SBP  ADDIN EN.CITE [,,]. Data from the Prospective Studies Collaboration showed that each 20-mmHg increase in SBP doubles the risk of CHD death []; conversely, each 10-mmHg reduction in SBP reduces CHD events by about one-quarter []. Estimates from the INTERHEART case-control study have indicated that globally, around one-fifth of the risk of an acute MI can be attributed to hypertension, and individuals with a history of hypertension had a ~2-fold risk of MI than those without history of hypertension  ADDIN EN.CITE []. Although evidence indicates a relatively strong association between BP and CHD, in the current analysis, this relationship was not as robust as previously reported. The increase in coronary event risk associated with a 10-mmHg increase in baseline SBP was small and did not reach statistical significance. This may be due to coronary events in the TNT, IDEAL, and CARDS trials being adjudicated by an expert panel, whereas events reported in prior studies may not have been as rigorously assessed; moreover, coronary and cardiovascular endpoints may have been grouped together.
4.2. LDL-C and cardiovascular risk 
Epidemiologic studies have shown that individuals with elevated cholesterol are at increased risk of future coronary events  ADDIN EN.CITE [,], and the benefit of LDL-C lowering for reducing the risk of coronary events is supported by statin clinical trial data  ADDIN EN.CITE []. Large meta-analyses of randomized statin trials have demonstrated a proportional reduction in risk of coronary events of ~20% for each 1-mmol/L (38.6-mg/dL) reduction in LDL-C, with risk reductions consistently observed across genders, treatment intensities, and levels of vascular risk  ADDIN EN.CITE [,]. In our pooled analysis, the risk of coronary events among a large population of high-risk patients increased by 5% for every additional increment of 10 mg/dL in baseline LDL-C.
While LDL-C and other lipid fractions have demonstrated a clear correlation with CHD incidence, the relationship between plasma cholesterol and stroke is less clear, as observational and clinical trial data have provided conflicting findings. As with our analysis, the Prospective Studies Collaboration meta-analysis did not identify a correlation between cholesterol and stroke  ADDIN EN.CITE [,]. However, some observational studies have demonstrated an association between cholesterol and ischemic stroke  ADDIN EN.CITE [,,]. Additionally, large clinical trials and meta-analyses of statin therapy in patients with or without CVD have shown these agents to be highly effective in reducing stroke risk  ADDIN EN.CITE [,,,,,,,,,]. In TNT, treatment with atorvastatin 80 mg resulted in a 25% relative reduction in stroke risk and a 23% relative reduction in cerebrovascular (stroke and TIA) risk versus atorvastatin 10 mg  ADDIN EN.CITE []. Each 1-mg/dL (0.03-mmol/L) change in on-treatment LDL-C was associated with a 0.5% change in the risk of stroke (p = 0.041) and a 0.6% change in the risk of a cerebrovascular event (p = 0.002) []. Furthermore, in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study, treatment with atorvastatin 80 mg provided a 16% relative reduction in the risk of stroke versus placebo in patients with recent stroke or TIA but without CHD  ADDIN EN.CITE [], with a continuous relationship observed between LDL-C reduction and stroke risk reduction  ADDIN EN.CITE []. Interestingly, however, although the CARDS trial demonstrated that treatment with atorvastatin 10 mg versus placebo resulted in a 48% reduction in the relative risk of stroke in primary prevention patients with type 2 diabetes  ADDIN EN.CITE [], none of the baseline lipid/lipoprotein concentrations or ratios examined was predictive of stroke in the CARDS population  ADDIN EN.CITE [,].
4.3. Cholesterol, statins, and stroke 
The conflicting findings regarding the association between LDL-C, statin-mediated lipid lowering, and stroke risk might be attributed to the heterogeneity of stroke pathophysiology and the differing roles that cholesterol plays in the etiology of different stroke subtypes. Data from the MRFIT study showed that while higher serum cholesterol levels were positively associated with death from non-hemorrhagic stroke, they were inversely related to hemorrhagic stroke mortality  ADDIN EN.CITE []. Hence, contrasting associations between cholesterol and ischemic versus hemorrhagic stroke may mask an overall relationship with total stroke. An analysis of cerebrovascular events in TNT found that of 291 stroke events experienced by 272 patients, 54% were ischemic, 25% embolic, 12% hemorrhagic, and 9% of unknown cause. The risk of stroke was consistently lower with atorvastatin 80 mg versus 10 mg for all stroke subtypes []. In CARDS, of 60 strokes experienced as first events, 47 (78%) were non-hemorrhagic and 13 (22%) were of indeterminate cause. Treatment with atorvastatin 10 mg was associated with a 50% relative reduction in the risk of non-hemorrhagic stroke compared with placebo  ADDIN EN.CITE []. In IDEAL, of 325 patients with stroke, only 12 (3.7%) patients experienced hemorrhagic stroke; however, compared with simvastatin 20 mg, intensive lipid-lowering with atorvastatin 80 mg did not significantly reduce the risk of fatal or nonfatal stroke  ADDIN EN.CITE []. That baseline LDL-C was not predictive of stroke events in this analysis of pooled data from these three trials might be attributed to the heterogeneity in stroke subtypes across the studies.
While the evidence that statin therapy can significantly reduce the risk of cerebrovascular events in a wide range of patient populations is unequivocal, whether the reduction in stroke risk is achieved via LDL-C reduction or through mechanisms independent of cholesterol lowering requires further investigation. Given that many ischemic strokes are caused by thromboemboli from the carotid arteries, the finding that each 10% reduction in LDL-C reduces carotid artery intima-media thickness by 0.73% per year [] provides an insight into the mechanism by which statin-mediated lipid lowering might prevent stroke. Regional differences in hydrostatic pressure between the cerebral and coronary vasculatures, and the differential effect this may have on macrophage activation and foam cell formation in atherosclerotic lesions, may also offer an explanation for why statins are equally effective in preventing both ischemic stroke and CHD events despite cholesterol being weakly predictive of cerebrovascular events. Higher hydrostatic pressure, as found within the cerebral vasculature, has been shown to increase lipid uptake and foam cell formation by macrophages, possibly via pressure-induced scavenger receptor expression []. Thus, while LDL-C may be less predictive of stroke, lipid lowering will still prevent LDL uptake by macrophages both in the cerebral and coronary circulation.
4.4. Predictors of cardiovascular risk in patients with diabetes 
By combining the data from patients with diabetes from TNT, IDEAL, and CARDS, we investigated the effect of baseline SBP and LDL-C on the risk of CHD and stroke in a large cohort of diabetic patients. Relationships between SBP and LDL-C and cardiovascular outcomes in the diabetic cohort were broadly similar to those seen in the overall population. Baseline SBP significantly predicted cardiovascular events, but not coronary events and stroke; baseline LDL-C significantly predicted cardiovascular and coronary events, but not stroke. Surprisingly, we found no association between baseline SBP, or history of hypertension, and increased risk of stroke in the diabetic population, despite an observed association between baseline SBP and stroke in the overall population. The lack of association in the diabetic cohort might be due to the analysis being insufficiently powered to identify an association between elevated BP and stroke risk in this smaller cohort.
4.5. Study limitations
The following limitations should be considered when interpreting these results. First, as a post-hoc analysis of clinical trial data, there may be residual confounders that have not been accounted for in our analysis. Second, there were differences in how medical history and cardiovascular events were defined and recorded between the TNT, IDEAL, and CARDS studies, which may also lead to confounding. Third, as noted, the smaller sample size of the diabetic subpopulation may have impeded the detection of risk associations due to underpowering.
4.6. Conclusions
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Baseline characteristics of the study populations.
Characteristic	TNT(n = 10,001)	CARDS	IDEAL(n = 8888)a	Pooled(n = 21,727)a
		Total population (n = 2838)	Placebo group(n = 1410)		
Age, years	61.0 ± 8.8	61.7 ± 8.1	61.8 ± 8.0	61.7 ± 9.5	61.4 ± 9.0
Men	8099 (81.0)	1929 (68.0)	957 (67.9)	7187 (80.9)	17,215 (79.2)
Smoking status					
Never	2338 (23.4)	983 (34.6)	485 (34.4)	1858 (20.9)	5179 (23.8)
Previous	6322 (63.2)	1223 (43.1)	601 (42.7)	5191 (58.4)	12,736 (58.6)
Current	1341 (13.4)	631 (22.2)	323 (22.9)	1835 (20.6)	3807 (17.5)
Diabetes	1501 (15.0)	2838 (100)	1410 (100)	1069 (12.0)	5408 (24.9)
Hypertension	5413 (54.1)	2256 (79.5)	1116 (79.1)	2924 (32.9)	10,592 (48.8)
SBP, mmHg	131 ± 16.8	144 ± 16.0	144 ± 16.1	137 ± 20.0	135 ± 18.6
History of IHDb	58 (0.6)	1 (0.0)	0 (0)	3641 (41.0)	3700 (17.0)
History of stroke/TIA	129 (1.3)	6 (0.2)	3 (0.2)	234 (2.6)	369 (1.7)
BMI, kg/m2	28.5 ± 4.6	28.8 ± 3.6	28.8 ± 3.5	27.3 ± 3.8	28.1 ± 4.2
Lipids, mg/dL					
LDL-C	98 ± 18	117 ± 27	117 ± 27	122 ± 35	110 ± 29
Triglycerides	151 ± 71	172 ± 96	171 ± 96	149 ± 78	153 ± 78
HDL-C	47 ± 11	54 ± 13	55 ± 13	46 ± 12	48 ± 12
Values are number (%) for categorical variables or mean ± SD for continuous variables.
To convert mg/dL to mmol/L for cholesterol, multiply by 0.02586; for triglycerides, multiply by 0.01129.
aIn IDEAL, four subjects had missing data for baseline smoking status.
bBased on a review of terms suggestive of IHD; some patients with this condition may have been missed.






Incidence of CHD and stroke events in the total and diabetic TNT, CARDS, IDEAL, and pooled populations.
Population	CHD event	Stroke event
Total populations		
TNT (n = 10,001)	2,404 (24.0)	272 (2.7)
CARDS (n = 2838)	128 (4.5)	60 (2.1)
IDEAL (n = 8888)	1,957 (22.0)	325 (3.7)
Pooled (n = 21,727) 	4,489 (20.7)	657 (3.0)
Diabetic populations		
TNT (n = 1501)	460 (30.6)	80 (5.3)
CARDS (n = 2838)	128 (4.5)	60 (2.1)
IDEAL (n = 1069)	261 (24.4)	67 (6.3)
Pooled (n = 5408)	849 (15.7)	207 (3.8)
Values are number (%) of patients who experienced a CHD or stroke event.




























	Incremental increases in SBP/LDL-C predicted future CV events in high-risk patients
	These effects appeared to differ between the coronary and cerebrovascular systems
	Determining various contributions of risk factors to CV risk could improve CVD care
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